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Alzheimer’s disease has a devastating impact on its victims by causing severe neurode-
generation in the brain that leads to a certain death. Only in a small number of cases can
the origin be traced to a variety of genetic mutations, for the greater part the reasons for
its onset are unclear. The defining factor is the formation of extracellular senile amyloid
plaques in the brain, but therapeutic approaches to remove them remain to be shown
effective in humans. Here we investigate physical processes that are involved in the re-
lease of the extracellular amyloid, by scrutinizing the intracellular domain of its precursor
protein. We identify a phenomenon that has never before been discussed in the context
of protein research: Like ice and water together, the intracellular domain of the amyloid
precursor protein can form a complex of phase coexistence with another protein. This
leads to an inherent instability that could well be among the missing pieces in the puzzle
of Alzheimer’s disease.
The neurological origin of Alzheimer’s disease is very complex, especially since there appear to be
both genetic and environmental factors [1]-[5] . Its hallmark symptom is the accumulation of extracel-
lular β-amyloid (Aβ) deposits in the brain [6]-[8]. These are derived from the transmembrane amyloid
precursor protein (APP) by proteolytic cleavages [8]-[10]. The APP has several isoforms, it is present in
many organs, and its exact physiological function remains under a debate [9]-[11]. The understanding of
the proteolytic processing of APP is also lacking [9]-[11] but there appears to be two different pathways.
The dominant one is the nonamyloidogenic pathway. It starts with an α-secretase that cleaves APP at
an ectoplasmic bond which is located within the domain of the Aβ [12], [9]. This prevents the generation
of Aβ and instead the outcome is an extracellular derivative and a membrane bound fragment. The
latter is further cleaved by a γ-secretase into a small p3 peptide that might locate in the extracellular
senile plaques, in addition of an isoform of the APP intracellular domain (AICD). The alternative, amy-
loidogenic pathway gives rise to the extracellular Aβ peptides that correlate with Alzheimer’s disease
[12], [9]. It starts with a β-secretase that cleaves APP at an ectoplasmic bond. This is followed by a
transmembrane γ-secretase that in parallel with the nonamyloidogenic pathway produces an isoform of
the intracellular AICD. During this process the γ-secretase also liberates the extracellular Aβ, and the
accretion of its Aβ42 isoform into amyloid fibrils in neuritic plaques is widely presumed to be the cause
of Alzheimer’s disease [6]-[8]. The correlation between these plaques with the Alzheimer’s disease has
motivated several Aβ based immunotherapic proposals to cure the disease. Most of them attempt to
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directly clear or prevent the cerebral Aβ deposits [13]-[15]. Unfortunately, these approaches have serious
side-effects such as the development of aseptic meningoencephalitis [16]-[18]. Thus, at the moment we
do not know for sure whether a direct targeting of the Aβ42 isoform will cure or even curb the disease
in humans. We do not even know for sure whether the senile plaques are a cause or merely a symptom.
The disease might as well commence upstream in the APP processing, the excess production of Aβ42
might just be an indication that something else has gone wrong [11], [19].
Here we chase for the causes of Alzheimer’s disease by scrutinizing the physical properties of the
protein complexes that relate to the APP cleavage. In particular, we search for an intracellular agent
that could potentially have relevance for understanding the onset of the Aβ42 production. In the
intracellular domain APP can bind to the Fe65 family of nuclear multidomain adaptor proteins [9],
[20]-[22]. This binding can influence both APP trafficking and metabolism [22]. After the γ/ cleavage
of APP the AICD may then form a transcriptionally active complex with Fe65. At the moment the
relation between AICD and Alzheimer’s disease is not known. But AICD is a product and Fe65 is a
participant in the proteolytic cleavage processing of APP into Aβ42, and Fe65 already appears among
the potential therapeutic targets [20], [21], [15].
In isolation AICD is presumed to be an intrinsically unstructured protein, there is no structural
data available in Protein Data Bank (PDB) that could be used to inspect its physical properties.
However, upon binding to Fe65, AICD can assume a regular form that has been analyzed with x-ray
crystallography. Here we shall concentrate on the data that is available in PDB under the code 3DXC
(chain B) [23], it describes a complex of a 28 residue segment of AICD with Fe65. We note that there are
also the closely related 3DXD and 3DXE, these can be analyzed similarly and with similar conclusions.
We have observed that the 3DXC complex has very interesting physical properties that sets it apart
from all but a very few protein complexes: This AICD/Fe65 complex is an example of an apparently
previously unrecorded but seemingly systematic phenomenon that we call protein phase coexistence.
Like ice together with water the two proteins in this complex are in two different phases. As such, an
oligomer that displays the rare and inherently unstable phenomenon of phase coexistence is for sure an
interesting object for future research. But since the delicate balance of the AICD/Fe65 complex has
the supplementary potential of being an important piece in the puzzle to find a cure for Alzheimer’s
disease, there are additional good reasons to investigate its physical properties.
The phases of a protein and more generally those of a polymer, are characterized by the scaling
properties of its radius of gyration Rg. Asymptotically, in the limit where the number N of monomers
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becomes very large [24]
Rg =
1
N
√
1
2
∑
i,j
(ri − rj)2 ≈ R0 ·Nν (1)
Here ri are the coordinates of the backbone Cα, the pre-factor R0 is an effective inter-monomer distance
that is independent of N , and ν is a compactness index that equals the inverse fractal dimension of
the backbone. The remarkable property of (1) is that ν is a universal quantity, it is independent of
temperature and chemistry. Different values of ν correspond to different phases, and once we know R0
we can unanimously compute the radius of gyration by simply counting the number of monomers. The
values of R0 summarize all the detailed physical properties of a polymer, all the effects of temperature
and chemical microstructure and atomary level details of a polymer are contained in the value of this
a priori non-universal and polymer specific pre-factor. As a consequence the relation (1) becomes truly
precious only in those exceptional circumstances where R0 assumes no more than a small number of
different values that are independent of temperature, chemistry and atomary level details. We propose
that in the case of proteins such different, clearly identifiable trajectories (1) that are labelled by the
different well defined values of R0 are the protein analogs of the Regge trajectories in high energy physics
[25].
We now recall the three major phases of proteins and other polymers [24]: In a bad solvent such
as under physiological conditions a protein normally collapses into a space filling conformation with
ν ≈ 1/3. For a fully flexible chain we have ν ≈ 1/2 while in the self-avoiding random walk phase we
have the Flory value ν ≈ 3/5, and this phase takes place in a good solvent environment. Finally, as a
potential fourth phase that is commonly overlooked, we point out that if ν ≈ 1 the protein looses its
inherently fractal structure and becomes more like a one dimensional rigid rod. Examples of this phase
are monotonous α-helices and β-strands that have no additional twists, turns or loops.
In Figure 1a we confirm that the large majority of all proteins in PDB are in the ν ≈ 1/3 collapsed
phase. In this Figure we plot all those individual unique chain proteins in PDB that have resolution
less than 2.0 A˙ and homology equivalence which is less than 30%, they are all located below the Flory
line ν = 3/5. The majority of proteins clearly assemble around the Regge trajectory
R(1)g ≈ 2.286 ·N0.37 (2)
Moreover, we observe no indication of trajectories where ν ≈ 3/5 or ν ≈ 1/2. We remind that there
is no obvious reason why R0 should have this common value for practically all proteins. The diffuse
scattering of entries in Figure 1a between the Regge trajectory (2) and the ν = 3/5 Flory line probably
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Figure 1: a) The (N,Rg) distribution of unique chain PDB proteins with resolution less than 2.0 A˙ and
with less than 30% homology equivalence. The red line is the Regge trajectory (2) and blue line is a
ν = 3/5 Flory line. It is notable that there are practically no unique chain entries above this Flory line.
b) All proteins currently in PDB that are above the Flory line. The two Regge trajectories (3) and (4)
are clearly visible.
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describes proteins that are in the collapsed ν ≈ 1/3 phase but have different R0 values. (Additional
ν ≈ 1/3 trajectories have been discussed [26], [27]. Here it is sufficient to note only the presence of the
trajectory that we clearly identify in Figure 1a.)
But our careful scrutiny of PDB data reveals that there are two additional, previously unobserved
and clearly distinct Regge trajectories that are located above the Flory line. These two trajectories are
visible in Figure 1b, they are
R(2)g ≈ 0.48 ·N0.973 (3)
R(3)g ≈ 1.02 ·N0.94 (4)
These trajectories both have ν very close to one. We presume that they are in the same universality
class, the difference in ν is a finite size effect. This is the universality class of one dimensional rods and
sticks, unlike the three conventional polymer phases it has no fractal structure.
We find that the trajectory (3) includes several membrane proteins and viral capsomers and an
example of the latter is 1AIK in PDB, while the trajectory (4) is mainly populated by collagen proteins
such as for example 2CUO in PDB. In both trajectories the proteins commonly appear in complexes with
several sub-chains that are each located on the same Regge trajectory. This prompts us to conclude that
the interactions between the individual sub-chains provides the mutually supportive lattice structure,
like a protein crystal, that protects the sub-chains against a collapse into the physiologically stable
ν ≈ 1/3 phase.
Remarkably, there are also protein complexes in the trajectories (3), (4) that do not follow the
structural pattern of collagens, membrane proteins and viral capsomers. In particular, we have found
that there is a small number of oligomers composed of proteins on different Regge trajectories. These
complexes have some sub-chains on the collapsed ν ≈ 1/3 trajectory of Figure 1a and some sub-
chains on the uncollapsed ν ≈ 1 trajectories in Figure 1b. Such oligomers are then examples of a
previously unrecorded phenomenon of protein phase coexistence: The collapsed ν ≈ 1/3 proteins provide
a stable supportive lattice structure that maintains the ν ≈ 1 components in their inherently unstable
uncollapsed conformation, possibly with the goal that they eventually attain a proper collapsed or
unstructured [28] conformation that they need in order to fulfill their biological mission. We have found
two different classes of phase coexistent oligomers. The first class consists of an apparently single protein
but with multiple sub-chains that are in different phases. The present PDB codes for these proteins
are 1WDC, 1G72, 1GOT, 1HTR, 1LTS, 2FP7, 2RIV, 3ABK, 3ARC, 3CX5, 3DBO. The second class
is formed by complexes with two or more a priori different proteins, and the present PDB codes are
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Figure 2: The distribution of individual chains on the (N,Rg) plane in the second class of phase
coexistent complexes. The data clearly accumulates around the blue line that describes the Regge
trajectory (3) and the red line that describes the Regge trajectory (2).
1L2W, 1JDH, 1TH1, 2F8X, 2EPV, 2PRR, 2BFX, 2D7C, 2VGO, 2K8F, 2QKH, 3EGG, 3HTU, 3HPW,
3IXS and 3DXC (3DXD, 3DXE). In Figure 2 we display the distribution of the individual sub-chains
of the second class in the (N,Rg) plane, they clearly gather around the Regge trajectories (2) and (3).
The two most notable complexes in the second class are 2K8F and 3DXC (3DXD, 3DXE). The former
is a bound state formed by the ”molecular interpreter” p300 [29], [28] in the Regge trajectory (3), with
the tumor suppressing protein p53 in the trajectory (2). The second is the one of interest here, the
Alzheimer related AICD/Fe65 complex with AICD in the trajectory (3) and Fe65 in the trajectory (2).
We now proceed to analyze the peculiar physical properties of this complex.
In Figure 3a we display the Cα backbone Frenet frame bond and torsion angles of the AICD protein
in 3DXC. This Figure reveals that the AICD consists of two very closely located loops that are separated
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Figure 3: a) The spectrum of backbone Frenet frame bond angles ψi (red line) and torsion angles θi
(black line) for the AICD component of 3DXC (chain B). b) The same spectrum after we have translated
the first loop so that it becomes locked by the proline at site 669, as described in the text. We use PDB
indexing for the sites.
from each other by a very short β-strand. We can describe the profile of each of these angles using an
elementary function: For the backbone bond angles we have [30], [31]
ψi = arccos
{
ri+1 − ri
|ri+1 − ri| ·
ri − ri−1
|ri − ri−1|
}
=
m1 · ec1(i−s) −m2 · e−c2(i−s)
ec1(i−s) + e−c2(i−s)
∈ [−π, π] mod (2π) (5)
The backbone torsion angles can be computed in terms of the bond angles from [30], [31]
θi = −12
a
1 + b · ψ2i
∈ [−π, π] mod (2π) (6)
and the parameter values are listed in Table I: The corresponding (ψi, θi) profiles (5), (6) describe
the first loop at sites 676-683 (we use PDB indexing) with RMSD accuracy of 0.29 A˙ and the second
loop at sites 681-688 with RMSD accuracy of 0.17 A˙. Both accuracies are substantially better than the
experimental B-factor accuracies.
In Table I we also list the number of times each of these loops appear in PDB with RMSD accuracy
0.5 A˙ or better. We find that they are both relatively abundant in the ν ≈ 1/3 Regge trajectory
proteins. In fact, at the outset there is nothing in the secondary structures of this AICD fold that
appears unusual for a protein in the collapsed ν ≈ 1/3 phase. Nevertheless it is very accurately, almost
exactly, located on the ν ≈ 1 Regge trajectory (3).
7
Table 1: Parameter values for the two loops in Figure 2.
Loop position m1 m2 c1 c2 s RMSD (A˙) Matches
1 676-683 51.51683 51.76632 2.98393 2.98280 679.9085 0.29 177
2 681-688 39.27430 38.617241 3.32735 3.34706 682.1742 0.17 896
Since the compactness index ν is universal and can only have definite discrete values, any continuous
local deformation of the protein shape can never cause any kind of discontinuous transition such as a
jump between the two phases ν ≈ 1 and ν ≈ 1/3. This makes the present combination of the two loops
in AICD highly unusual: Even if we continuously translate these two loops apart from each other along
the backbone by shifting the value s in (5) that determines the position of the center of the loop, we
can never reach a collapsed Regge trajectory. We will always remain in the ν ≈ 1 phase. A scrutiny of
the amino acid structure reveals that AICD has a proline at site 669. Since proline commonly anchors
a loop when a protein is in isolation, we propose that the presence of Fe65 prevents the first loop from
sliding towards its natural position, where it becomes attached with Pro(669). We note that there is
another proline at the site 685 that appears to stabilize the position of the second loop. Using the
explicit profile (5), (6) we can investigate what might happen if the first soliton starts sliding towards
Pro(669) along the backbone. For this we do nothing more than shift the value of the parameter s
in (5) from the value in Table I accordingly. In Figure 4 we show how the radius of gyration Rg of
the AICD depends on the position of the first loop as we slide it towards Pro(669) while keeping the
second loop anchored by Pro(685); the final (ψi, θi) profile is displayed in Figure 3b. We observe that
Rg increases monotonically when the two loops drift apart. When the first loop reaches the position
where it becomes locked by Pro(669), we find that the ensuing AICD configuration has relocated itself
from the Regge trajectory (3) to the Regge trajectory (34). Since it should be highly natural for a
protein to always try and locate itself on a Regge trajectory, we propose that these are the two most
likely configurations of AICD in the complex with Fe65. The presence of two natural alternatives is an
indicative of a genetic switching mechanism. It would be highly interesting to find out how the biological
function of the AICD/Fe65 complex differs between these two unfolded conformations of AICD, when
the complex becomes translocated to the nucleus and participates in gene transcription. Is there a
correlation with the onset of Alzheimer’s disease? Moreover, the genetic switch could even operate
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Figure 4: The evolution of the radius of gyration for the AICD in 3DXC (chain B), during the translation
of its first loop to the proline at site 669; see also Figure 3b.
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solely around Pro(669), the first soliton could conceivably be on either side of this proline. Suppose it
is located on the other side of Pro(669) when the γ/ cleavage takes place. It could then become part
of Aβ. Could this cause the formation of senile amyloid plaques?
In isolation, the ν ≈ 1 phase of AICD must be extremely unstable under in vivo conditions, we
have not found any single strand protein above our ν = 3/5 Flory line. Consequently in isolation the
AICD should be subject to a phase transition that takes it into the collapsed ν ≈ 1/3 trajectory. This
necessarily entails a global change in the loop structure: We propose that when the two proteins become
disengaged, AICD collapses either in a process where the two loops first pair-annihilate each other and
a new loop structure is formed to bring about the phase transition, or alternatively there could be the
formation of a new loop near Pro(669). It could also be that AICD enters a highly unstructured and
dynamic state where the first loop bounces back and forth between the two prolines, causing AICD
to oscillate between the two ν ≈ 1 Regge trajectories (3) and (4). Other alternatives also exist. For
example the first loop could become locked by Pro(669), and the relatively long β-strand could then
buckle to form a new loop. Maybe a NMR experiment could be designed to reveal what goes on?
In conclusion, we have identified a novel physical phenomenon in proteins, the presence of a phase co-
existence. An example is the intracellular AICD/FE65 oligomer with PDB code 3DXC (3DXD, 3DXE),
a direct participant in the processes that cause the accumulation of Alzheimer’s disease related Aβ42
deposits in the brain. We have argued that like ice in water, in this complex the AICD conformation is
inherently unstable. Our analysis of its loop structure reveals that there are at least 5-6 different and
physiologically plausible conformations and pathways that AICD can follow to ”melt”. It is already
known to bind together with Fe65 into the state described by 3DXC. Alternatively the first AICD loop
may move apart from the second loop and become stabilized by Pro669 in a conformation that is located
along the Regge trajectory (4). This transition between the two ν ≈ 1 Regge trajectories within the
complex could act as a switch that influences the way how it participates in gene transcription. The
Regge trajectory (4) conformation can also collapse to ν ≈ 1/3 state due to a buckling of the ensuing
relatively long β-strand. The AICD may also depart the complex with Fe65, and enter an unstructured
dynamic configuration where its first loop initially bounces back and forth to cause an oscillatory motion
between the two ν ≈ 1 Regge trajectories. These two loops can eventually pair-annihilate, followed by
the formation of a new loop state that causes collapse into the ν ≈ 1/3 state. There could also be an
AICD collapse either in isolation or in a complex with Fe65 due to the formation of a new loop structure
following Pro(669).
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AICD is presumed to have a roˆle in transcription and it may also have pro-apoptosic effects. Con-
sequently it should be of interest to analyze the physiological impacts of the different pathways the
AICD/Fe65 complex can follow. In particular, we propose to investigate the correlations between the
AICD Regge trajectory properties, the different loop pathways of the AICD/Fe65 complex, their causal
connection to the excess formation of Aβ42 and the onset of Alzheimer’s disease. Like ice and water
together, the AICD/Fe65 complex is in a highly unstable state of phase co-existence. The fairly unique
physical and presumably also physiological properties of this rare state might well hold a clue how to
understand and maybe even cure Alzheimer’s disease.
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